Dr. Brian Dong, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Louisville School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 239
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Louisville School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 51631 -
Internal Medicine Physician
KY license 51631 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uofl Health - Jewish Hospital and Mary & Elizabeth Hospital Louisville, KY
- Baptist Health Hardin Elizabethtown, KY
- University of Louisville Hospital Louisville, KY
Medical groups
- University of Louisville Physicians Inc (1,445 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 239
- Services billed
- 748
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 155 | 70 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 148 | 63 |
| Established patient office or other outpatient visit, 20-29 minutes | 51 | 40 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 39 | 38 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 28 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Louisville, KY | 331 |
| Kisqali (ribociclib succinate) | 51 |
| Gabapentin Other prescribers in Louisville, KY | 45 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Louisville, KY | 41 |
| Verzenio (abemaciclib) | 35 |
| Ondansetron Hcl Other prescribers in Louisville, KY | 34 |
| Alendronate Sodium Other prescribers in Louisville, KY | 31 |
| Pantoprazole Sodium Other prescribers in Louisville, KY | 26 |
| Eliquis (apixaban) Other prescribers in Louisville, KY | 23 |
| Exemestane | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 160 payments worth $10,156 in total to this clinician.
| Pfizer Inc. | $4,147 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,454 |
| Daiichi Sankyo Inc. | $729 |
| Novartis Pharmaceuticals Corporation | $489 |
| Gilead Sciences, Inc. | $463 |
| Merck Sharp & Dohme LLC | $298 |
| Lilly USA, LLC | $191 |
| Stemline Therapeutics Inc. | $186 |
| Consulting Fee | $5,970 |
|---|---|
| Food and Beverage | $4,174 |
| Education | $12.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 18, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $2,160 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Consulting Fee Truqap · Oncology | $2,010 |
| Pfizer Inc. Jun 18, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,800 |
| Gilead Sciences, Inc. Dec 18, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4267481;G360;12665445 | $12.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $308,628 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A phase 1 dose escalation and expansion study to evaluate safety tolerability pharmacokinetic pharmacodynamic and antitumor activity of PF07248144 in participants with advanced or metastatic solid tumors
Pfizer Inc. - Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC
Genentech, Inc. - A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.